EchoIQ Ltd
Echo IQ Limited is an Australia-based company.
The business
Echo IQ Limited is an Australia-based company. It is an artificial intelligence (AI) and medical technology company. The Company uses AI-driven technology and proprietary software to improve decision-making in cardiology. The principal activity of the Company is the development of AI software that aids in predicting Aortic Stenosis heart condition. The Company's EchoSolv platform harnesses AI-driven analysis of echocardiographic data to assist clinicians in detecting aortic stenosis and other conditions. Its EchoSolv product allows users to assess echocardiographic studies against diagnostic guidelines for structural heart conditions. EchoSolv automatically identifies patients at risk of structural heart disease. EchoSolv improves the standard clinical workflow associated with diagnosis and treatment. The Company's subsidiaries include HWH Software Pty Ltd, Echo IQ Global Pty Ltd and Echo IQ Incorporated.
Small Caps Research
No research on EchoIQ Ltd yet
We cover the ASX small-cap market one company at a time. Request coverage and we’ll prioritise EIQ based on demand.
Share price
Market Statistics
Valuation
Trading Activity
Performance
Latest news
Echo IQ to Review Regulatory Path after EchoSolv HF Application Misses FDA Clearance
Echo IQ studies next steps after FDA finds EchoSolv HF 510(k) not substantially equivalent; will engage FDA directly while EchoSolv AS stays cleared.
Echo IQ Secures Exclusive Advara Data Licence to Expand Cardiovascular AI Platform
Echo IQ lands exclusive Advara data licence, unlocking up to 1 million de-identified echocardiograms to power its EchoSolv cardiovascular AI platform.
Echo IQ and Pro Medicus Join Forces to Market Echosolv Cardiac Platform to US Healthcare Sector
Echo IQ and Pro Medicus announce up to $20m investment to market EchoSolv HF AI cardiac platform in the US; reseller deal to accelerate adoption.
Echo IQ Secures Mayo Clinic Collaboration to Assess Cardiac Risk in Cancer Patients
Echo IQ teams with Mayo Clinic Arizona to test AI-driven cardiac risk scores from echocardiography in cancer patients; results expected 2027.
Looking for charts & signals? See the tab.
Unlock the full research library - free.
Create a free account to access every broker report, CEO interview, IPO alert, and daily market wrap. No credit card. No paywall.